Medical isotope developer IsoRay Medical has announced a distribution agreement with Oncura, a GE Healthcare subsidiary, to distribute its OncoSeed I-125 brachytherapy seed.
Richland, WA-based IsoRay expects that the ability to offer I-125 seeds will allow it to expand cesium-131 sales through group purchasing organization contracts that require multiple sources from a single provider.
Further, IsoRay anticipates strategic value in supporting customers who have not yet converted their practice to cesium-131 for the treatment of a variety of anatomic sites including prostate.
Related Reading
IsoRay adds Canadian distributor, November 18, 2009
IsoRay touts cesium-131 treatment, September 28, 2009
IsoRay's 2009 results dip, September 24, 2009
IsoRay nets FDA OK on seeds, August 18, 2009
IsoRay sales drop, loss narrows, May 18, 2009
Copyright © 2009 AuntMinnie.com
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
